Results 91 to 100 of about 56,924 (160)

BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. [PDF]

Exp Mol Med, 2023
Zeng F, Li Y, Meng Y, Sun H, He Y, Yin M, Chen X, Deng G.   +7 more
europepmc   +1 more source

Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. [PDF]

J Enzyme Inhib Med Chem, 2023
Negri A, Marozzi M, Trisciuoglio D, Rotili D, Mai A, Rizzi F.   +5 more
europepmc   +1 more source

Epigenome Modifying Tools In Asthma [PDF]

, 2015
Adcock,, Brook, PO, Durham, AL, Perry, M
core   +1 more source

From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors. [PDF]

Eur J Med Chem, 2023
Koravovic M, Mayasundari A, Tasic G, Keramatnia F, Stachowski TR, Cui H, Chai SC, Jonchere B, Yang L, Li Y, Fu X, Hiltenbrand R, Paul L, Mishra V, Klco JM, Roussel MF, Pomerantz WC, Fischer M, Rankovic Z, Savic V.   +19 more
europepmc   +1 more source

BET-inhibitor DYB-41 reduces pulmonary inflammation and local and systemic cytokine levels in LPS-induced acute respiratory distress syndrome: an experimental rodent study

Intensive Care Medicine Experimental
Background Acute respiratory distress syndrome (ARDS) is a form of respiratory failure stemming from various underlying conditions that ultimately lead to inflammation and lung fibrosis.
Manuela Iten, Camille Gschwend, Alessandro Ostini, David Robert Cameron, Christine Goepfert, David Berger, Matthias Haenggi   +6 more
doaj   +1 more source

BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation. [PDF]

Mol Cancer Res, 2023
Chen H, Gesumaria L, Park YK, Oliver TG, Singer DS, Ge K, Schrump DS.   +6 more
europepmc   +1 more source

Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors. [PDF]

ACS Med Chem Lett, 2023
Bamborough P, Chung CW, Goodwin NC, Mitchell DJ, Neipp CE, Phillipou A, Preston A, Prinjha RK, Soden PE, Watson RJ, Demont EH.   +10 more
europepmc   +1 more source

The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling

Experimental Hematology & Oncology
Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the range of mutations that can arise in AML ...
Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Yerdanos Asemelash, Steven Sher, Britten K. Gordon, Ethan C. Whipp, Shaneice Mitchell, Bonnie K. Harrington, Shelley Orwick, Samon Benrashid, Virginia M. Goettl, Vedat Yildiz, Andrew D. Mitchell, Olivia Cahn, Alice S. Mims, Karilyn T. M. Larkin, Meixao Long, James Blachly, Jennifer A. Woyach, Rosa Lapalombella, Nicole R. Grieselhuber   +21 more
doaj   +1 more source

mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. [PDF]

JCI Insight, 2023
Kumari A, Gesumaria L, Liu YJ, Hughitt VK, Zhang X, Ceribelli M, Wilson KM, Klumpp-Thomas C, Chen L, McKnight C, Itkin Z, Thomas CJ, Mock BA, Schrump DS, Chen H.   +14 more
europepmc   +1 more source

Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties. [PDF]

ACS Med Chem Lett, 2022
Hill MD, Fang H, Norris D, Delucca GV, Huang H, DeBenedetto M, Quesnelle C, Schmitz WD, Tokarski JS, Sheriff S, Yan C, Fanslau C, Haarhoff Z, Huang C, Kramer M, Madari S, Menard K, Monereau L, Morrison J, Raghavan N, Shields EE, Simmermacher-Mayer J, Sinz M, Tye CK, Westhouse R, Xie C, Zhang H, Zhang L, Zvyaga T, Lee F, Gavai AV, Degnan AP.   +31 more
europepmc   +1 more source